1.68

2.04% -0.035

Aytu Biopharma Inc (AYTU)

Overview News Price History Financials Why AYTU Down? Discussions Forecast Stock Split

Aytu Biopharma Inc stock is traded at $1.68, with a volume of 41,266. It is down -2.04% in the last 24 hours and up +21.74% over the past month. Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Previous Close:

$1.715

Open:

$1.8

24h Volume:

41,266

Relative Volume:

1.20

Market Cap:

$10.33M

Revenue:

$93.76M

Net Income/Loss:

$-13.68M

P/E Ratio:

-0.6388

EPS:

-2.63

Net Cash Flow:

$8.77M

1W Performance:

+2.44%

1M Performance:

+21.74%

6M Performance:

-39.78%

1Y Performance:

-33.60%

1-Day Range:

$1.68

$1.80

1-Week Range:

$1.595

$1.93

52-Week Range:

$1.3001

$3.45

Aytu Biopharma Inc Stock (AYTU) Company Profile

Name

Aytu Biopharma Inc

Sector

Healthcare (1176)

Industry

Drug Manufacturers - Specialty & Generic (1)

Phone

(720) 437-6580

Address

7900 E. UNION AVENUE, DENVER

Employee

102

Twitter

@aytubioscience

Next Earnings Date

2024-12-13

Latest SEC Filings

AYTU's Discussions on Twitter

Compare AYTU with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AYTU Aytu Biopharma Inc	1.68	10.33M	93.76M	-13.68M	8.77M	-2.63
ZTS Zoetis Inc	167.53	75.58B	9.15B	2.43B	2.31B	5.32
HLN Haleon Plc Adr	9.24	41.78B	14.26B	1.55B	0	0.3383
TAK Takeda Pharmaceutical Co Adr	13.10	41.53B	30.27B	1.93B	3.45B	0.6044
TEVA Teva Pharmaceutical Industries Ltd Adr	21.82	24.72B	16.77B	-959.00M	1.37B	-0.85
NBIX Neurocrine Biosciences Inc	145.88	14.77B	2.24B	385.90M	440.10M	3.73

Aytu Biopharma Inc Stock (AYTU) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-30-21	Initiated	Cantor Fitzgerald	Overweight
May-29-20	Initiated	H.C. Wainwright	Buy

Aytu Biopharma Inc Stock (AYTU) Latest News

Jan 18, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Shares Fly 28% But Investors Aren't Buying For Growth - Simply Wall St

Jan 18, 2025

Jan 06, 2025

Aytu BioPharma to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025 - AccessWire

Jan 06, 2025

Aytu BioPharma CEO to Present Growth Strategy at Lytham Partners Healthcare Summit - StockTitan

Jan 06, 2025

Jan 02, 2025

Aytu BioPharma, Inc. (NASDAQ:AYTU) Sees Large Growth in Short Interest - Defense World

Jan 02, 2025

Dec 27, 2024

An unknown company affiliated with Jonathan Hughes acquired Innovus Pharmaceuticals, Inc. from Aytu BioPharma, Inc.. - Marketscreener.com

Dec 27, 2024

Aytu BioPharma, Inc. (NASDAQ:AYTU) Is About To Turn The Corner - Simply Wall St

Dec 27, 2024

Dec 14, 2024

Aytu BioScience stock hits 52-week low at $1.4 amid market challenges - Investing.com Australia

Dec 14, 2024

Aytu BioScience stock hits 52-week low at $1.4 amid market challenges By Investing.com - Investing.com South Africa

Dec 14, 2024

Dec 06, 2024

Aytu BioPharma Announces Settlement Approval Hearing for Derivative ClaimsOn December 3, 2024, Aytu BioPharma, Inc. (NASDAQ: AYTU), a Delaware corporation, made a significant disclosure regarding the settlement of certain derivative claims in the Wi - Defense World

Dec 06, 2024

Dec 05, 2024

Aytu BioPharma Proposes Settlement in Shareholder Lawsuit - Yahoo Finance

Dec 05, 2024

Dec 03, 2024

Aytu BioPharma Reaches Settlement Agreement in Derivative Action LawsuitKey Details for Shareholders - StockTitan

Dec 03, 2024

Aytu BioPharma Disclosure Notification - AccessWire

Dec 03, 2024

Tesla CEO Elon Musk's $56B pay package rejected by Delaware judge - Yahoo Finance

Dec 03, 2024

Nov 22, 2024

Aytu BioPharma Ranked as One of Fastest-Growing Companies in North America on the 2024 Deloitte Technology Fast 500(TM) - AccessWire

Nov 22, 2024

Aytu BioPharma Makes Deloitte Fast 500 List for 4th Year, EBITDA Soars 162% | AYTU Stock News - StockTitan

Nov 22, 2024

Nov 18, 2024

Aytu BioPharma, Inc. Appoints Ryan Selhorn as Corporate Secretary and Treasurer - Marketscreener.com

Nov 18, 2024

Aytu BioPharma First Quarter 2025 Earnings: Beats Expectations - Simply Wall St

Nov 18, 2024

Nov 16, 2024

Aytu BioPharma Announces Fiscal 2025 First Quarter Results and CFO Transition - Defense World

Nov 16, 2024

Nov 15, 2024

Aytu BioPharma, Inc. (NASDAQ:AYTU) Q1 2025 Earnings Call Transcript - Insider Monkey

Nov 15, 2024

Investors Don't See Light At End Of Aytu BioPharma, Inc.'s (NASDAQ:AYTU) Tunnel And Push Stock Down 32% - Simply Wall St

Nov 15, 2024

Nov 14, 2024

Aytu BioPharma, Inc. Reports Earnings Results for the First Quarter Ended September 30, 2024 - Marketscreener.com

Nov 14, 2024